Exforge HCT is a combination of three different medications that are used to treat high blood pressure. It contains two different types of drugs, which are an angiotensin II receptor blocker (ARB) and a diuretic. The combination of these two medications helps to lower blood pressure more effectively than either medication alone. Exforge HCT has been approved by the U.S. Food and Drug Administration (FDA) and is available in both generic and brand-name forms. This article will provide a comprehensive guide to the benefits of Exforge HCT and how it can help to manage high blood pressure.
Exforge HCT is a combination of two different medications, amlodipine and valsartan. Amlodipine is a type of calcium channel blocker, which helps to relax blood vessels and reduce the amount of pressure that is put on them. Valsartan is an angiotensin II receptor blocker (ARB), which works to block the action of a hormone called angiotensin II. This hormone can cause the blood vessels to narrow, which can raise blood pressure. The third medication in Exforge HCT is hydrochlorothiazide, which is a diuretic. Diuretics help to reduce the amount of fluid in the body, which can reduce the amount of pressure on the blood vessels.
Exforge HCT works by combining the effects of the three medications. The amlodipine helps to relax the blood vessels, reducing the amount of pressure on them. The valsartan blocks the action of angiotensin II, which helps to keep the blood vessels from narrowing. The hydrochlorothiazide helps to reduce the amount of fluid in the body, which reduces the pressure on the blood vessels. All three medications work together to help lower blood pressure.
Exforge HCT can provide a number of benefits for those with high blood pressure. These benefits include:
Exforge HCT can cause a number of side effects, including:
Exforge HCT is not recommended for those with certain medical conditions, including:
1.
Major Shifts in Urothelial Cancer Care: Immunotherapy Redefines Standards
2.
Two medications might work better for breast cancers that are resistant to one.
3.
Living near St. Louis-area Coldwater Creek during childhood linked with higher risk of cancer from radiation
4.
Resection for Early Liver Cancer Tied to Improved Survival.
5.
Researchers publish action plan to address appendiceal cancer enigmas
1.
Management of Relapsed Synovial Sarcoma: Current Treatment Strategies and Emerging Therapies
2.
MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed
3.
Claudin-18.2 in Gastric Cancer: Tumor-Stroma Crosstalk and Disease Progression
4.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
5.
The latest research on Thyroid Cancer: Symptoms, Diagnosis, and Treatment Options
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
2.
Efficient Management of First line ALK-rearranged NSCLC - Part III
3.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
4.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
5.
An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation